Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suppression of Prostate Cancer by Naftopidil (SNAP)
jRCTs031180176Active, not recruiting
- Sponsor
- The University of Tokyo
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of naftopidil in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) (2 arms), sponsored by The University of Tokyo. Primary endpoint: Time to prostate cancer diagnosis. Started Feb 2017; status: active, not recruiting.
02
Drugs
naftopidil
03
Conditions
prostate cancer (PCa)benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on jRCTs031180176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180176.